Are you curious about biosimilar medications? According to Health Canada, a biosimilar is a biologic drug that closely matches an already approved biologic, with no significant differences in safety or effectiveness. In British Columbia, biosimilars for denosumab, a widely used biologic medication, are now available. These alternatives are typically more affordable, benefiting both patients and the healthcare system.
If you're considering switching to a biosimilar or starting on one, there are criteria to meet based on your coverage type:
PharmaCare-funded patients: BC PharmaCare has introduced a transition plan for eligible patients starting August 2024.
Patients with extended health benefits: Check your plan’s coverage details.
Patients paying out-of-pocket: Review pricing options with your healthcare provider.
For more information, the BC Coalition of Osteoporosis Physicians (BCCOP) provides a comprehensive guide.
If you’d like to deepen your understanding of biologic, biosimilar, and generic drugs, Osteoporosis Canada offers free webinars for both patients and healthcare providers:
For Patients: Biosimilar for Patients on Denosumab by Dr. Teri Charrois.
For Healthcare Providers: Biologics & Biosimilars Overview by Dr. Allan Low and Information on Biosimilar for Denosumab by Dr. Angela Cheung.
If you have questions about whether a biosimilar is right for you, consult your healthcare provider or pharmacist for personalized advice.